Baird analyst David Rescott maintains $Boston Scientific (BSX.US)$ with a buy rating, and maintains the target price at $100.
According to TipRanks data, the analyst has a success rate of 48.0% and a total average return of 1.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has experienced a quarter that exceeded forecasts in all aspects, notwithstanding already lofty expectations. The company's shares are currently experiencing pressure due to the temporary halt of the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient segment. It is critical to recognize that this patient group is not currently receiving treatment, observations are under review, and it is anticipated that enrollment will recommence shortly.
Boston Scientific is recognized for its 'best in medtech growth,' with expectations for its revenue growth to not only be robust but also to contribute positively to margins, bolstered by one of the most extensive pipelines in the medical technology sector.
Boston Scientific's Q3 results were described as 'impressive', with management raising its 2024 guidance to exit the year with a +15% organic sales growth. Despite a temporary pause in the EP trial, AVANTGUARD, and the stock's subsequent decline, such a reaction is deemed excessive following key opinion leader checks.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
貝雅分析師David Rescott維持$波士頓科學 (BSX.US)$買入評級，維持目標價100美元。
根據TipRanks數據顯示，該分析師近一年總勝率為48.0%，總平均回報率為1.5%。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
波士頓科學在所有方面均超過預期的季度，儘管預期已經很高。 由於AVANt GUARD臨床試驗的暫時中止，該公司股價目前受到壓力，該試驗正在針對新的患者群體對Farapulse進行調查。 需要認識到這個患者群體目前並未接受治療，觀察正處於審查階段，預計很快將恢復招募。
波士頓科學以其醫療科技行業中的「最佳增長」而聞名，預計其營業收入增長不僅強勁，而且還將積極貢獻於利潤率，得益於在醫療科技板塊中擁有最爲廣泛的管道之一。
波士頓科學的第三季度業績被描述爲『令人印象深刻』，管理層將其2024年指導方針提高至以+15%有機銷售增長退出年。 儘管EP試驗AVANTGUARD暫時暫停，股價隨後下跌，但這種反應被認爲是根據關鍵意見領袖反饋過度的。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
